TET2 cascade: a novel regulator of chromatin structure and leukaemogenesis
2024
TET2's Role in Chromatin Structure and Leukaemia
publication
Evidence: high
Author Information
Author(s): Dempke Wolfram C. M., Fenchel Klaus
Primary Institution: Medical Clinic III, University Medical School, Munich, Germany
Hypothesis
TET2 regulates chromatin structure and leukaemogenesis in stem cells and leukaemia cells.
Conclusion
The study reveals that TET2 mutations disrupt chromatin structure, contributing to leukaemogenesis and offering potential for new therapies.
Supporting Evidence
- TET2 mutations can be detected in 12-34% of myeloid malignancies.
- Mutated TET2 is a key driver for leukaemogenesis.
- TET2 interacts with genes like FLT-3 and WT1, affecting chemotherapy resistance.
- MBD6 binding is disrupted by mutated TET2, leading to increased chromatin accessibility.
Takeaway
TET2 helps control how genes are turned on and off in blood cells, and when it’s broken, it can lead to cancer.
Methodology
The study involved examining the interactions of TET2 with other proteins and its effects on chromatin structure in leukaemia cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website